The personalised blood test can analyse up to 48 mutations that are unique to a patient’s tumour. Credit: Cancer Research UK.

A new study funded by Cancer Research UK has shown that a personalised blood test can be used to identify the risk of lung cancer returning.

Developed by biotech company Inivata, the liquid biopsy, called RaDaR, has the ability to pick up tiny fragments of DNA released into the blood as tumours grow.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Lung Cancer Circulating Tumour DNA (LUCID-DNA) study showed how circulating tumour DNA (ctDNA) is able to reveal a tumour’s state, location and weaknesses.

This helps clinicians select appropriate treatments for patients.

Many early-stage non-small cell lung cancer patients can be cured with either surgery, radiotherapy or, sometimes, (chemo)radiotherapy.

See Also:

These treatments are followed up with tests, including CT scans, to find out if the tumour has been successfully removed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, the scans cannot pick up the tiny quantities of cancer cells, called minimal residual disease (MRD), that can regrow into further tumours.

The LUCID-DNA study is aimed at finding out if circulating DNA can be detected in early-stage lung cancers using the RaDaR test.

The test can analyse up to 48 mutations that are unique to a patient’s tumour.

Cancer Research UK Cambridge Institute group leader and Inivata chief scientific officer Dr Nitzan Rosenfeld said: “If cancer cells remain in the body after treatment a tumour can regrow. If that happens, it is a big setback for patients and the doctors treating them.

“Liquid biopsy can be used to detect tiny amounts of residual cancer after treatment, flagging those patients who have signs that their tumour may not have been eradicated completely with treatment.

“We’re hoping that this technology could help doctors decide when additional rounds of treatment are needed and could save lives.”